University Hospital conducts a clinical trial of Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19

The University Hospital Schleswig-Holstein is commencing recruitment for the clinical trial of the Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19.

The condition is COVID-19.

A new clinical trial is recruiting patients in the following locations: Germany.

The trial officially began on the February 1, 2021 and is planned to complete on December 2021.

Based on the literature, it seems likely that a nutritional intervention with nicotinamide (a form of vitamin B3) can support the therapy of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19) by, e.g., improving the availability of tryptophan and its metabolism-supporting metabolites (e.g. NAD). A pilot phase of the COVit trial showed an effect of nicotinamide on the time to complete resolution of COVID-19 symptoms. In addition, diarrhoea is a common symptom of COVID-19.

Among the inclusion criteria are:

• SARS-CoV-2 infection confirmed by laboratory findings; the positive test must not date back more than 7 days.
• Relevant infection symptoms, e.g. in the respiratory or gastrointestinal tract.
• The patient has been able to give written consent via a website before any trial procedure is performed and can comply with the trial-dependent prerequisites and requirements.

The University Medical Center Schleswig-Holstein (UKSH), is a university hospitals, located in Kiel and Lübeck in Germany and Europe. Its aim is to ensure medical care in Schleswig-Holstein.

The Faculty of Medicine at the University of Kiel and the Medicine Section at the University of Lübeck are responsible for academic medicine in Schleswig-Holstein.

The focus of research at the Universities of Kiel and Lübeck at the UKSH lies partially within the fields of “Infection and inflammation”, “The brain, hormones and behavior”, “Genetic medicine” and “Age-independent mechanisms for the manifestation of disease”, “Oncology”, “Clinical genome research”, “Neuroscience”, “Endocrinal management and regulation” and “Biomedical technologies”.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04751604